MoonLake Immunotherapeutics

MLTX · NASDAQ

$10.32+$0.57 (+5.85%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $9.75

Latest news

NewsAug 10, 1:21 PM ETVandana Singh
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
Press releaseAug 10, 7:00 AM ETGlobe Newswire
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
NewsJun 24, 8:03 AM ETAvi Kapoor
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
NewsJun 22, 8:03 AM ETVandana Singh
Why Is MoonLake Immunotherapeutics Stock Soaring Monday?
Press releaseJun 21, 5:00 PM ETGlobe Newswire
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
NewsJun 1, 7:18 AM ET
Moonlake Immunotherapeutics Inks Master Commercial Supply Agreement With Vetter Pharma To Manufacture One Or More Application Systems Pre-filled With An Active Pharmaceutical Ingredient, Placebo Or Other Material For Moonlake-8K
NewsMay 11, 11:44 AM ETVandana Singh
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
Press releaseMay 10, 9:00 AM ETGlobe Newswire
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
NewsApr 8, 7:08 AM ETVandana Singh
Insmed Drug Misses Primary Goal, Program Axed
NewsMar 30, 11:27 AM ETVandana Singh
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
Press releaseMar 28, 3:00 PM ETGlobe Newswire
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
NewsFeb 23, 9:10 AM ETVandana Singh
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
Press releaseFeb 22, 11:00 AM ETGlobe Newswire
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Press releaseFeb 10, 7:00 AM ETGlobe Newswire
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
NewsFeb 2, 2:25 PM ETVandana Singh
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
NewsFeb 2, 8:02 AM ET
MoonLake Immunotherapeutics Announces FDA Grants Fast Track Designation For Sonelokimab To Treat Moderate‑To‑Severe Palmoplantar Pustulosis
Press releaseFeb 2, 8:00 AM ETGlobe Newswire
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
NewsJan 9, 12:35 PM ET
10 Health Care Stocks Whale Activity In Today's Session
NewsJan 9, 7:18 AM ETAvi Kapoor
This Sphere Entertainment Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
NewsJan 8, 2:06 PM ETVandana Singh
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
NewsJan 8, 12:33 PM ETAvi Kapoor
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
NewsJan 8, 12:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsJan 8, 10:20 AM ETAvi Kapoor
Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday
Press releaseJan 8, 9:32 AM ETGlobe Newswire
Morning Market Pulse: From Orbit to Biomaterials, Innovation Drives the Tape
Press releaseDec 15, 1:01 PM ETPRNewswire
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
Press releaseDec 15, 12:00 PM ETBusiness Wire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
Press releaseDec 15, 10:46 AM ETGlobe Newswire
MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm
Press releaseDec 15, 9:34 AM ETBusiness Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Press releaseDec 15, 9:00 AM ETPRNewswire
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Press releaseDec 15, 8:55 AM ETBusiness Wire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Press releaseDec 15, 3:27 AM ETPRNewswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
Press releaseDec 15, 3:25 AM ETPRNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Press releaseDec 13, 1:07 PM ETGlobe Newswire
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
Press releaseDec 13, 9:21 AM ETGlobe Newswire
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
Press releaseDec 13, 7:18 AM ETGlobe Newswire
MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15
Press releaseDec 12, 8:51 PM ETBusiness Wire
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Press releaseDec 12, 4:00 PM ETPRNewswire
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
Press releaseDec 12, 11:46 AM ETPRNewswire
MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
Press releaseDec 12, 11:21 AM ETPRNewswire
MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
Press releaseDec 12, 9:00 AM ETPRNewswire
MoonLake Immunotherapeutics Class Action: Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
Press releaseDec 11, 12:53 PM ETGlobe Newswire
MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
Press releaseDec 11, 9:00 AM ETPRNewswire
MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX
NewsOct 6, 6:23 AM ETAvi Kapoor
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
NewsSep 29, 1:14 PM ETAvi Kapoor
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings
NewsSep 29, 10:11 AM ETAvi Kapoor
Nasdaq Jumps 150 Points; US Pending Home Sales Rise
NewsSep 29, 8:06 AM ETAvi Kapoor
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsSep 29, 5:07 AM ETAvi Kapoor
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Why Is MoonLake Immunotherapeutics Stock Soaring Monday?

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

Moonlake Immunotherapeutics Inks Master Commercial Supply Agreement With Vetter Pharma To Manufacture One Or More Application Systems Pre-filled With An Active Pharmaceutical Ingredient, Placebo Or Other Material For Moonlake-8K

FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Insmed Drug Misses Primary Goal, Program Axed

MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

MoonLake Immunotherapeutics Announces FDA Grants Fast Track Designation For Sonelokimab To Treat Moderate‑To‑Severe Palmoplantar Pustulosis

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

10 Health Care Stocks Whale Activity In Today's Session

This Sphere Entertainment Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

12 Health Care Stocks Moving In Thursday's Intraday Session

Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday

Morning Market Pulse: From Orbit to Biomaterials, Innovation Drives the Tape

MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

MoonLake Immunotherapeutics Class Action: Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

MLTX 4-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings

Nasdaq Jumps 150 Points; US Pending Home Sales Rise

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket